All In Biotech

Drug Trial Radar · NCT07157254

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects With Deletion- or Nondeletion-type Angelman Syndrome

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

55

Actual

Start

Oct 13, 2025

Primary completion

Oct 30, 2026

Study completion Oct 30, 2026

Sponsor

Lead sponsor
Ultragenyx Pharmaceutical IncIndustry
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goal of the study is to evaluate the safety and efficacy of GTX-102 in participants with Angelman syndrome.

Conditions

  • Angelman Syndrome

Interventions

  • No interventionOther

    During the no treatment period participants do not receive any study drug

  • GTX-102Drug

    antisense oligonucleotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subprotocol A/B/C/D: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), Severe Events, and Events Related to Investigational Product, Procedure, and PremedicationTime frame: Up to Day 506
  2. Subprotocol A Only: Bayley-4 Cognitive Without Caregiver Input Raw Score Change from Baseline at Day 338Time frame: Baseline, Day 338
  3. Subprotocol B/D Only: Multidomain Responder Index (MDRI) Net Response at Day 338Time frame: Baseline, Day 338
  4. Subprotocol C Only: MDRI Net Response at Day 338Time frame: Baseline, Day 338

Locations

21 sites in 8 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Rush University Medical Center

    Chicago, Illinois

  • Kennedy Kreiger Institute

    Baltimore, Maryland

  • Clinical Trial Site

    Kansas City, Missouri

  • Rare Disease Research

    Hillsborough, North Carolina

  • Akron Children's Hospital

    Akron, Ohio

  • UT Health Austin

    Austin, Texas

  • Carum Research Inc.

    Dallas, Texas

  • Hospital Universitario Austral

    Pilar, Buenos Aires, Argentina

  • Hospital de Crianças César Pernetta e Hospital Pequeno Príncipe

    Curitiba, Paraná, Brazil

  • Casa dos Raros

    Santa Cecília, Porto Alegre, Brazil

  • Hopital de la Timone

    Marseille, France

  • Necker-Enfants Malades Hospital

    Paris, France

  • Sheba Medical Center

    Ramat Gan, Israel

  • Azienda Ospedaliera Universitaria Meyer IRCCS

    Florence, Italy

  • Fondazione IRCCS Istituto Neurologico C. Besta

    Milan, Italy

  • Clinical Trial Site

    Rome, Italy

  • Hospital de Santa Maria

    Lisbon, Portugal

  • Hospital Santa Joao

    Porto, Portugal

  • Clinical Trial Site

    London, United Kingdom

  • University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.